Influence of Metformin Discontinuation on Readmission Rate in Patients With Acute Heart Failure

Overview

Journal J Community Hosp Intern Med Perspect

Date 2024 Oct 11

PMID 39391108

Authors

Curtis Wong

Erica Junqueira

Nayda P Poldiak

Nancy Crossley

Shantae Jenkins

Affiliations

Soon will be listed here.

Abstract

Background: The consequences of discontinuing metformin in patients with heart failure have not been determined. Knowing that acute exacerbation of chronic heart failure contributes to substantial increases in major adverse cardiovascular events (MACE), we proposed a retrospective study to examine whether discontinuing metformin in patients hospitalized with heart failure impacts mortality and readmission rates.

Methods: We conducted a retrospective analysis of patients admitted with a diagnosis of acute heart failure to hospitals in the HCA Healthcare System from 2020 to 2022. Included patients had a prior diagnosis of diabetes mellitus, acute heart failure, and were taking metformin prior to admission. After applying our exclusion criteria, a total of 7740 patients remained. The primary outcomes were 30-, 60-, and 90-day readmission rates and secondary outcomes were mortality and length of stay.

Results: Patients who were discharged without a prescription for metformin (NONDIS-MET) were 4.489 (95% CI 3.673-5.488, p < 0.0001) times more likely to have a MACE outcome in 30 days compared to patients who received a discharge order for metformin (DIS-MET). The findings were similar for 60-day and 90-day readmission rates, with NONDIS-MET patients 3.457 (95% CI 2.893-4.131, p < 0.0001) and 2.992 (95% CI 2.534-3.533 p < 0.0001) times more likely to have a MACE outcome than MET patients, respectively. However, when metformin was continued during the patients' hospital stay (CONT-MET) there was no significant association with MACE outcomes, readmission, or mortality rates.

Conclusion: We found that diabetic patients admitted with acute heart failure exacerbations had a higher incidence of major adverse cardiac events and were more likely to be readmitted when they were not prescribed metformin after discharge. Our findings agree with prior work showing the cardioprotective effects of metformin; however, continuing metformin during hospital admission did not affect our patients adverse outcomes.

References

Crowley M, Diamantidis C, McDuffie J, Cameron C, Stanifer J, Mock C . Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med. 2017; 166(3):191-200. PMC: 5293600. DOI: 10.7326/M16-1901. View

Shah D, Fonarow G, Horwich T . Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010; 16(3):200-6. PMC: 2855621. DOI: 10.1016/j.cardfail.2009.10.022. View

Facila L, Fabregat-Andres O, Bertomeu V, Navarro J, Minana G, Garcia-Blas S . Metformin and risk of long-term mortality following an admission for acute heart failure. J Cardiovasc Med (Hagerstown). 2016; 18(2):69-73. DOI: 10.2459/JCM.0000000000000420. View

Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A . Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2010; 4(1):53-8. PMC: 3046634. DOI: 10.1161/CIRCHEARTFAILURE.110.952556. View

Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R . Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovasc Diabetol. 2021; 20(1):74. PMC: 8004411. DOI: 10.1186/s12933-021-01264-z. View

El Messaoudi S, Rongen G, de Boer R, Riksen N . The cardioprotective effects of metformin. Curr Opin Lipidol. 2011; 22(6):445-53. DOI: 10.1097/MOL.0b013e32834ae1a7. View

Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha S . The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. Heart Fail Rev. 2017; 23(3):445-459. DOI: 10.1007/s10741-017-9666-8. View

Eurich D, Majumdar S, McAlister F, Tsuyuki R, Johnson J . Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28(10):2345-51. DOI: 10.2337/diacare.28.10.2345. View

Eurich D, Weir D, Majumdar S, Tsuyuki R, Johnson J, Tjosvold L . Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013; 6(3):395-402. DOI: 10.1161/CIRCHEARTFAILURE.112.000162. View

10.

Lambadiari V, Dimitriadis G, Kadoglou N . The impact of oral anti-diabetic medications on heart failure: lessons learned from preclinical studies. Heart Fail Rev. 2018; 23(3):337-346. DOI: 10.1007/s10741-018-9690-3. View

11.

Tanner C, Wang G, Liu N, Andrikopoulos S, Zajac J, Ekinci E . Metformin: time to review its role and safety in chronic kidney disease. Med J Aust. 2019; 211(1):37-42. DOI: 10.5694/mja2.50239. View

12.

DeFronzo R, Fleming G, Chen K, Bicsak T . Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016; 65(2):20-9. DOI: 10.1016/j.metabol.2015.10.014. View

13.

Xu Z, Zhang H, Wu C, Zheng Y, Jiang J . Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies. Front Cardiovasc Med. 2022; 9:944902. PMC: 9539433. DOI: 10.3389/fcvm.2022.944902. View

14.

Connelly P, Lonergan M, Soto-Pedre E, Donnelly L, Zhou K, Pearson E . Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. Diabetes Obes Metab. 2017; 19(11):1579-1586. PMC: 5655780. DOI: 10.1111/dom.12978. View

15.

Gao J, Yuan J, Wang Q, Lei T, Shen X, Cui B . Metformin protects against PM-induced lung injury and cardiac dysfunction independent of AMP-activated protein kinase α2. Redox Biol. 2019; 28:101345. PMC: 6838896. DOI: 10.1016/j.redox.2019.101345. View

16.

Varjabedian L, Bourji M, Pourafkari L, Nader N . Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs. 2018; 18(3):181-193. DOI: 10.1007/s40256-018-0266-3. View

17.

Masoudi F, Inzucchi S, Wang Y, Havranek E, Foody J, Krumholz H . Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005; 111(5):583-90. DOI: 10.1161/01.CIR.0000154542.13412.B1. View

18.

Usman A, Bliden K, Cho A, Walia N, Jerjian C, Singh A . Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis. 2022; 53(2):363-371. PMC: 8764325. DOI: 10.1007/s11239-022-02631-7. View

19.

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

20.

Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V . Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998; 338(13):867-72. DOI: 10.1056/NEJM199803263381303. View